Soluble cytokine receptors: Basic immunology and clinical applications

Critical Reviews in Clinical Laboratory Sciences

Volumn 36, Issue 3, 1999, Pages 165-224

  Fernandez Botran, Rafael ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Cytokines; Disease markers; Immunoregulation; Immunotherapy

Indexed keywords

CARRIER PROTEIN; CYTOKINE; CYTOKINE RECEPTOR; IMMUNOMODULATING AGENT; MARKER; MEMBRANE RECEPTOR;

ALTERNATIVE RNA SPLICING; AUTOIMMUNE DISEASE; BLOOD LEVEL; CANCER; COMPETITIVE INHIBITION; DISEASE ACTIVITY; HALF LIFE TIME; IMMUNOLOGY; IMMUNOREGULATION; INFLAMMATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; RECEPTOR BINDING; REVIEW; SEPSIS;

ANIMALS; CELL MEMBRANE; CYTOKINES; HEMATOPOIETIC STEM CELLS; HUMANS; INFLAMMATION; LYMPHOCYTES; RECEPTORS, CYTOKINE; SOLUBILITY;

EID: 0032816365     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408369991239196     Document Type: Review

References (243)

1. Vitetta ES, Fernandez-Botran R, Myers CD, et al. Cellular interactions in the humoral immune response. Adv Immunol 1989; 45: 1-105.
2. Arai K, Lee F, Miyajima A, et al. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 1990; 59: 783-836.
3. Oppenheim JJ, Saklatvala J. Cytokines and their receptors. In: Oppenheim JJ, Rossio J, Gearing AJH, eds. Clinical applications of cytokines: role in pathogenesis, diagnosis and therapy. Pp 3-15. New York: Oxford University Press, 1993.
4. Abbas AK, Lichtman AH Pober JS. Cellular and molecular immunology. 2nd ed. Philadelphia: Saunders, 1994.
5. Janeway CA, Travers P. Immunobiology. The immune system in health and disease. London: Current Biology/Garland Publishing, 1996.
6. Miyajima A, Kitamura T, Harada N, et al. Cytokine receptors and signal transduction. Annu Rev Immunol 1992; 10: 295-331.
7. Taga T, Kishimoto T. Cytokine receptors and signal transduction. FASEB J 1993; 6: 3387-3396.
8. Ihle JN, Witthuhn BA, Quelle FW, et al. Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol 1995; 13: 369-398.
9. Leonard WJ, O'Shea JJ. Jaks and Stats: biological implications. Annu Rev Immunol 1998; 16: 293-322.
10. Bach EA, Aguet M Schreiber RD. The IFNγ receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997; 15: 563-591.
11. Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J 1991; 5: 2567-2574.
12. Arend WP. Inhibiting the effects of cytokines in human diseases. Adv Intern Med 1995; 40: 365-394.
13. Fernandez-Botran R, Ma Y Chilton, PM. Soluble cytokine receptors: their roles in immunoregulation, disease and therapy. Adv Immunol 1996; 63: 269-336.
14. Heaney ML, Golde DW. Soluble receptors in human disease. J Leukocyte Biol 1998; 64: 135-146.
15. Aderka, D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cyt Growth Factor Rev 1996; 7: 231-240.
16. Paul WE. Pleiotropy and redundancy of T cell derived lymphokines in the immune responses. Cell 1989; 57: 521-524.
17. Smith KA. Interleukin-2: inception, impact and implications. Science 1988; 240: 1169-1176.
18. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253-278.
19. Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 1991; 77: 1627-1652.
20. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411-520.
21. Farrar MA, Schreiber RD. The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol 1993; 11: 571-611.
22. Dinarello CA. The biological properties of interleukin-1. Eur Cyt Network 1994; 5: 517-531.
23. Boehm U, Klamp T, Groot M, et al. Cellular responses to interferon-γ. Annu Rev Immunol 1997; 15: 749-795.
24. Gately MK, Renzetti LM, Magram J, et al. Interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998; 16: 495-521.
25. Sanderson CJ, Campbell HD Young IG. Molecular and cellular biology of eosinophil differentiation factor (interleukin-5) and its effects on human and mouse B cells. Immunol Rev 1988; 102: 29-50.
26. Schrader JW. The panspecific hemopoietin of activated T lymphocytes (interleukin-3). Annu Rev Immunol 1986; 4: 205-230.
27. Moore MAS. The clinical use of colony stimulating factors. Annu Rev Immunol 1991; 9: 159-191.
28. Goodwin RG, Lupton S, Schmierer A, et al. Human interleukin-7: molecular cloning and growth factor activity on human and murine B-lineage cells. Proc Natl Acad Sci USA 1989; 86: 302-306.
29. Dayer, JM, Burger D. Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur Cyt Netw 1994; 5: 563-571.
30. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357.
31. Muegge K, Durum SK. Cytokines and transcription factors. Cytokine 1990; 2: 1-8.
32. Caput D, Beutler B Hartog K, et al. Identification of a common nucleotide sequence in the 3′ untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 1986; 83: 1670-1674.
33. Black RA, Kronheim SR, Cantrell M, et al. Generation of biologically active interleukin 1-β by proteolytic cleavage of the inactive precursor. J BiolChem 1988; 263: 9437-9442.
34. Gearing AJH, Beckett P, Christodoulou M, et al. Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature 1994; 370: 555-557.
35. Hemler ME, Breumer MB, McLean JM, et al. Antigenic stimulation regulates the level of expression of interleukin-2 receptors on human T cells. Proc Natl Acad Sci USA 1984; 81: 2172-2175.
36. Lowenthal JW, Tougue C, MacDonald HR, et al. Antigenic stimulation regulates the expression of IL-2 receptors in a cytolytic T lymphocyte clone. J Immunol 1985; 134: 931-939.
37. Lowenthal JW, Greene WC. Contrasting interleukin-2 binding properties of the α (p55) and β (p70) protein subunits of the human high-affinity interleukin-2 receptor. J Exp Med 1987; 166: 1156-1161.
38. Wang HM, Smith KA. The interleukin-2 receptor. Functional consequences of its bimolecular structure. J Exp Med 1987; 166: 1055-1069.
39. Ohara J, Paul WE. Up-regulation of interleukin4/B-cell stimulatory factor 1 receptor expression. Proc Natl Acad Sci USA 1988; 85: 8221-8225.
40. Loughnan MS, Nossal GJV. Interleukins 4 and 5 control expression of IL-2 receptor on murine B cells through independent induction of its two chains. Nature 1989; 340: 76-79.
41. Kondo M, Takeshita T, Ishii N, et al. Sharing of the interleukin-2 (IL-2) receptor γ chain between receptors for IL-2 and IL-4. Science 1993; 262: 1874-1877.
42. Russell SM, Keegan AD, Harada N, et al. The interleukin-2 receptor γ chain is a functional component of the interleukin-4 receptor. Science 1993; 262: 1880-1883.
43. Minami Y, Kondo T, Miyazaki T, et al. The IL-2 receptor complex: its structure, function and target genes. Annu Rev Immunol 1993; 11: 245-267.
44. Sims JE, Gayle MA, Slack JL, et al. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci USA 1993; 90: 6155-6159.
45. Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993; 261: 472-475.
46. Hibi M, Murakami M, Saito M, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63: 1149-1157.
47. Davis S, Aldrich TH, Ip NY, et al. Released form of CNTF receptor α component as a soluble mediator of CNTF responses. Science 1993; 259: 1736-1739.
48. Sato TA, Widmer MB, Finkelman FD, et al. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 1993; 150: 2717-2723.
49. Fernandez-Botran R, Vitetta ES. Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins. J Exp Med 1991; 174: 673-681.
50. Aderka D, Engelmann H, Maor Y, et al. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323-329.
51. Ma Y, Hurst HE, Fernandez-Botran R. Soluble interleukin-4 receptors as carrier proteins: their effects on the pharmacokinetics of murine IL-4 in vivo. J Pharmacol Exp Ther 1996; 279: 340-350.
52. Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336-340.
53. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343: 341-346.
54. Sorg RV, Enczmann J, Sorg U, et al. Rapid and sensitive mRNA phenotyping for interleukins (IL-1 to IL-6) and colony-stimulating factors (G-CSF, M-CSF, and GM-CSF) by reverse transcription and subsequent polymerase chain reaction. Exp Hematol 1991; 19: 882-887.
55. Sorg RV, Enczmann J, Sorg U, et al. Identification of an alternatively spliced transcript of human interleukin-4 lacking the sequence encoded by exon 2. Exp Hematol 1993; 21: 560-563.
56. Brown JM, Muchmore AV Rosenstreich DL. Uromodulin, an immuno-suppressive protein derived from pregnancy urine, is an inhibitor of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 9119-9123.
57. Hession C, Decker JM, Sherblom AP, et al. Uromodulin (Tamm-Horsfall glycoprotein): a renal ligand for lymphokines. Science 1987; 237: 1479-1484.
58. 2-macroglobulin as a cytokine-binding plasma protein. J Biol Chem 1989; 264: 5818-5825.
59. 2-macroglobulin as a carrier protein for IL-6. J Immunol 1989; 142: 148-152.
60. 2-macroglobulin. Immunol Today 1990; 11: 163-166.
61. Suzuki H, Kamimura J, Ayabe T, et al. Demonstration of neutralizing autoantibodies against IL-1α in sera from patients with rheumatoid arthritis. J Immunol 1990; 145: 2140-2146.
62. Mae N, Liberate DF, Chizzonite R, et al. Identification of high-affinity anti-IL-1α autoantibodies in normal human serum as an interfering substance in a sensitive enzyme-linked immunosorbent assay for IL-1α. Lymphokine Cytokine Res 1991; 10: 61-68.
63. Takemura H, Suzuki H, Yoshizaki K, et al. Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis. Arthritis Rheum 1992; 35: 940-943.
64. Hansen MB, Svenson M, Diamant M, et al. High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. Cytokine 1993; 5: 72-80.
65. Jackson RL, Busch SJ Cardin AD. Glycosaminoglycans: molecular properties, protein interactions and role in physiological processes. Physiol Rev 1991; 71: 481-539.
66. Kjellen L, Lindahl A. Proteoglycans-structures and interactions. Annu Rev Biochem 1991; 60: 443-475.
67. Cockwell P, Adams DH Savage COS. Glycosaminoglycans contribute to multiple functions of vascular endothelial cells. Clin Exp Immunol 1996; 104: 1-3.
68. Tanaka Y, Adams DH Shaw S. Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Immunol Today 1993; 14: 111-115.
69. Spillman D, Lindahl U. Glycosaminoglycan-protein interactions: a question of specificity. Curr Opin Struct Biol 1994; 4: 677-682.
70. Roberts R, Gallagher J, Spooncer E, et al. Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature 1988; 332: 376-378.
71. Lortat-Jacob H, Grimaud JA. Interferon-γ C-terminal function: new working hypothesis. Heparan sulfate and heparin, new targets for IFN-γ protect, relax the cytokine and regulate its activity. Cell Mol Biol 1991; 37: 253-260.
72. Lantz M, Thysell H, Nilsson E, et al. On the binding of tumour necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 1991; 88: 2026-2031.
73. Ramsden L, Rider CC. Selective and differential binding of interleukin (IL)-α, IL-1β, IL-2 and IL-6 to glycosaminoglycans. Eur J Immunol 1992; 22: 3027-3031.
74. Tanaka Y, Adams DH, Hubscher S, et al. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1β. Nature 1993; 361: 79-82.
75. Finkelmann FD, Katona IM, Urban JF, Jr. et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990; 8: 303-333.
76. Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135: 3172-3177.
77. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-512.
78. Smith CA, Farrah T Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994; 76: 959-962.
79. Davis S, Aldrich TH, Valenzuela DM, et al. The receptor for ciliary neurotrophic factor. Science 1991; 253: 59-63.
80. Rubin LA, Galli F, Greene WC, et al. The molecular basis for the generation of human soluble interleukin-2 receptor. Cytokine 1990; 2: 330-335.
81. Mosley B, Beckman MP, March CJ, et al. The murine Interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell 1989; 59: 335-348.
82. Wrighton N, Campbell LA, Harada N, et al. The murine interleukin-4 receptor gene: genomic structure, expression and potential for alternative splicing. Growth Factors 1992; 6: 103-118.
83. Tavernier J, Devos R, Cornelis S, et al. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL-5-specific α chain and a β chain shared with the receptor for GM-CSF. Cell 1991; 66: 1175-1184.
84. Horiuchi S, Koyanagi Y, Zhou Y, et al. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol 1994; 24: 1945-1948.
85. Goodwin RG, Friend D, Ziegler SF, et al. Cloning of the human and murine interleukin-7 receptors: Demonstration of a soluble form and homology to a new receptor superfamily. Cell 1990; 60: 941-951.
86. Robb L, Hilton DJ, Wilson TA, et al. Structural analysis of the gene encoding the murine interleukin-11 receptor α-chain and a related locus. J Biol Chem 1996; 271: 13754-13761.
87. Novick D, Cohen B Rubinstein M. The human interferon α/β receptor: characterization and molecular cloning. Cell 1994; 77: 391-400.
88. Brown CB, Beaudry P, Laing TD, et al. In vitro characterization of the human recombinant soluble granulocyte-macrophage colony-stimulating factor receptor. Blood 1995; 85: 1488-1495.
89. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med 1990; 113: 619-627.
90. Honda M, Yamamoto S, Chang M, et al. Human soluble IL-6-receptor: Its detection and enhanced release by HIV infection. J Immunol 1992; 148: 2175-2180.
91. Chilton PM, Fernandez-Botran R. Production of soluble IL-4 receptors by murine spleen cells is regulated by T cell activation and IL-4. J Immunol 1993; 151: 5907-5917.
92. Cope AP, Aderka D, Wallach D, et al. Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF. Immunology 1995; 84: 21-30.
93. Symons JA, Eastgate JA Duff GW. A soluble binding protein specific for interleukin 1β is produced by activated mononuclear cells. Cytokine 1990; 2: 190-198.
94. Leeuwenberg JF, Dentener MA Buurman WA. Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes. Role of CD14, LPS binding protein, and bactericidal/permeabilily-increasing protein. J Immunol 1994; 152: 5070-5076.
95. Kuhns DB, Alvord WG Gallin JI. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infect Dis 1995; 171: 145-152.
96. Bemelmans MH, Abramowicz D, Gouma DJ, et al. In vivo T cell activation by anti-CD3 monoclonal antibody induces soluble TNF receptor release in mice. Effects of pentoxifylline, methylprednisolone, anti-TNF, and anti-IFN-gamma antibodies. J Immunol 1994; 153: 499-506.
97. Lotze MT, Custer MC, Sharrow SO, et al. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res 1987; 47: 2188-2195.
98. Voss SD, Hank JA, Nobis CA, et al. Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol Immunother 1989; 29: 261-269.
99. Chilton PM, Fernandez-Botran R. Regulation of the expression of the soluble and membrane forms of the murine IL-4 receptor. Cell Immunol 1997; 180: 104-115.
100. Lantz M, Malik S, Slevin ML, et al. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 1990; 2: 402-406.
101. Fernandez-Botran R, Wynn TA, Hieny S, et al. Linked in vivo expression of soluble interleukin-4 receptor and IL-4 in murine schistosomiasis. Eur J Immunol 1995; 25: 649-656.
102. Fernandez-Botran R, Chilton PM, Ma Y, et al. Control of the production of soluble interleukin-4 receptors: implications in immunoregulation. J Leuk Biol 1996; 59: 499-504.
103. Bismuth G, Leclercq L, Duphot M, et al. In vitro induction and expression of interleukin-2 receptor in a cloned T helper cell differentiation model. Cell Immunol 1984; 86: 90-100.
104. Smith KA, Cantrell D. Interleukin-2 regulates its own receptor. Proc Natl Acad Sci USA 1985; 82: 864-868.
105. Jacques Y, Le Mauff B, Boeffard F, et al. A soluble interleukin-2 receptor produced by a normal alloreactive human T cell clone binds interleukin-2 with low affinity. J Immunol 1987; 139: 2308-2316.
106. Baran D, Korner M Thèze J. Characterization of the soluble murine IL-2R and estimation of its affinity for IL-2. J Immunol 1988; 141: 539-546.
107. Treiger BF, Leonard WJ, Svetlik P, et al. A secreted form of the human interleukin-2 receptor encoded by an "anchor minus" cDNA. J Immunol 1986; 136: 4099-4105.
108. Kondo N, Kondo S, Shimizu A, et al. A soluble "anchorminus" interleukin-2 receptor suppresses in vitro interleukin 2-mediated immune responses. Immunol Lett 1988; 19: 299-308.
109. Debets R, Savelkoul HFJ. Cytokine antagonists and their potential therapeutic use. Immunol Today 1994; 15: 455-458.
110. Gessner A, Rollinghoff M. Soluble IL-4 receptor, potential for therapeutic and prophylactic intervention. Behring Inst Mitt 1994; 95: 35-41.
111. Maliszewski CR, Sato TA, Davison B, et al. In vivo biological effects of recombinant soluble interleukin-4 receptor. Proc Soc Exp Biol Med 1994; 206: 233-237.
112. Hale KK, Smith CG, Baker SL, et al. Multifunctional regulation of the biological effects of TNF-α by the soluble type I and type II TNF receptors. Cytokine 1995; 7: 26-38.
113. Mohler KM, Torrance DJ, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548-1561.
114. Finkelman FD, Madden KB, Morris SC, et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 1993; 151: 1235-1244.
115. May L, Neta R, Moldawer LL, et al. Antibodies chaperone circulating IL-6: paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo. J Immunol 1994; 151: 3225-3236.
116. Novick D, Shulman LM, Chen L, et al. Enhancement of interleukin-6 cytostatic effect on human breast carcinoma cells by soluble IL-6-receptor from urine and reversion by monoclonal antibody. Cytokine 1992; 4: 6-11.
117. Suzuki H, Yasukawa K, Saito T, et al. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur J Immunol 1993; 23: 1078-1082.
118. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993; 90: 11924-11928.
119. Schöbitz B, Pezeshki G, Pohl T, et al. Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. FASEB J 1995; 9: 659-664.
120. Akira S, Hirano T, Taga T, et al. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J 1990; 4: 2860-2867.
121. Estrov Z, Kurzrock R, Estey E, et al. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood 1992; 79: 1938-1945.
122. Van Leenen D, van der Poll T, Levi M, et al. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol 1993; 151: 2318-2325.
123. 2. Proc Natl Acad Sci USA 1989; 86: 3803-3807
124. Standiford TJ, Strieter RM, Chensue SW, et al. IL-4 inhibits the expression of IL-8 from stimulated human monocytes. J Immunol 1990; 145: 1435-1439.
125. Moore KW, O'Garra A, de Waal Maleyft R, et al. Interleukin-10. Annu Rev Immunol 1993; 11: 165-190.
126. Jacobs CA, Lynch DH, Roux E, et al. Characterization and pharmacokinetic parameters of recombinant soluble interleukin-4 receptor. Blood 1991; 77: 2396-2403.
127. Jacobs CA, Beckmann MP, Mohler K, et al. Pharmacokinetic parameters and biodistribution of soluble cytokine receptors. Int Rev Exp Pathol 1993; 34 Pt B: 123-135.
128. Ozmen L, Gribaudo G, Fountoulakis M, et al. Mouse soluble IFNγ receptor as IFNγ inhibitor. Distribution, antigenicity, and activity after injection in mice. J Immunol 1993; 150: 2698-2705.
129. Kürschner C, Garotta G Dembić Z. Construction, purification, and characterization of new interferon γ (IFNγ) inhibitor proteins. J Biol Chem 1992; 267: 9354-9360.
130. Peschon J, Torrance DS, Stocking KL, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998; 160: 943-952.
131. Lucas R, Lou J, Morel DR, et al. TNF receptors in the microvascular pathology of acute respiratory distress syndrome and cerebral malaria. J Leukocyte Biol 1997; 61: 551-558.
132. Seckinger P, Isaaz S Dayer JM. A human inhibitor of tumor necrosis factor α. J Exp Med 1988; 167: 1511-1516.
133. Engelmann HD, Aderka D, Rubinstein M, et al. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264: 11974-11980.
134. Olsson I, Lantz M, Nilsson E, et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989; 42: 270-275.
135. Gatanaga T, Lentz R, Masunaka I, et al. Identification of TNF-LT blocking factor(s)in the serum and ultrafiltrates of human cancer patients. Lymphokine Res 1990; 9: 225-229.
136. Seckinger P, Zhang JH, Hauptmann B, et al. Characterization of a tumor necrosis factor α (TNF-α) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci USA 1990; 87: 5188-5192.
137. Nophar Y, Kemper O, Brakebusch C, et al. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 1990; 9: 3269-3278.
138. Steinshamn S, Bemelmans MH, Buurman WA, et al. Granulocytopenia reduces the release of soluble TNF receptor p75 in endotoxin-stimulated mice: a possible mechanism of enhanced TNF activity. Cytokine 1995; 7: 50-56.
139. Mylius-Spencker H, Winzen R, Resch K, et al. Regulation of the expression of transmembrane and soluble 75 kDa tumor necrosis factor receptors by interferon-γ and granulocyte-macrophage colony stimulating factor involves transcriptional activation. Eur Cytokine Netw 1997; 8: 351-358.
140. Evans TJ, Moyes D, Carpenter A, et al. Protective effect of 55 kD but not 75 kD soluble TNF receptor-IgG fusion proteins in an animal model of Gram-negative sepsis. J Exp Med 1994; 180: 2173-2179.
141. Suter PM, Suter S, Girardin E, et al. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 1992; 145: 1016-1022.
142. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992; 35: 1160-1169.
143. Roux-Lombard P, Punzi L, Hasler F, et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36: 485-489.
144. Barrera P, Boerbooms AMT, Janssen EM, et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993; 36: 1070-1079.
145. Gattorno M, Picco P, Buoncompagni A, et al. Serum p55 and p75 tumor necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann Rheum Dis 1996; 55: 243-247.
146. Aderka D, Wysenbeek A, Engelmann H, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1111-1120.
147. Gabay C, Cakir N, Moral F, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997; 24: 303-308.
148. Mangge H, Kenzian H, Gallisti S, et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995; 38: 211-220.
149. Froon AH, Bemelmans MH, Greve TW, et al. Increased concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. Crit Care Med 1994; 22: 803-809.
150. Kern P, Hemmer CJ, Gallati H, et al. Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria. J Infect Dis 1992; 166: 930-934.
151. Deloron P, Roux-Lombard P, Ringwald P, et al. Plasma levels of TNF-α soluble receptors correlate with outcome in human falciparum malaria. Eur Cytokine Netw 1994; 5: 331-336.
152. Sarthou JL, Angel G, Aribot G, et al. Prognostic value of anti-Plasmodium falciparum-specific immunoglobulin G3, cytokines, and their soluble receptors in West African patients with severe malaria. Infect Immun 1997; 65: 3271-3276.
153. Kaufmann P, Tilz GP, Lueger A, et al. Elevated plasma levels of soluble tumor necrosis factor receptor (sTNFRp60) reflect severity of acute pancreatitis. Intensive Care Med 1997; 23: 841-848.
154. Keil M, Pec MK, Schenn G, et al. Value of serum soluble tumor necrosis factor concentrations in the diagnosis and prognosis of renal graft rejection. Nephrol Dial Transplant 1994; 9: 815-819.
155. Aderka D, Engelmann H, Hornik V, et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 1991; 51: 5602-5607.
156. Aderka, D, Granot V, Levavi H, et al. The value of soluble TNF receptors in predicting relapse of ovarian carcinoma. Eur Cytokine Netw 1994; 5: 217.
157. Jablonska E, Pietruska Z. Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients. Arch Immunol Ther Exp 1997; 45: 449-453.
158. Fossa SD, Aamdal S, Naume B, et al. Serum levels of cytokines and soluble cytokine receptors in patients with metastatic renal cell carcinoma or malignant melanoma receiving IL-2/interferon-α combination therapy. Acta Oncol 1995; 34: 599-603.
159. Warzocha K, Salles G, Bienvenu J, et al. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol 1997; 15: 499-508.
160. Kalinkovich A, Engelmann H, Burstein HR, et al. Elevated serum levels of soluble tumor necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin Exp Med 1992; 89: 351-355.
161. Hober D, Benyoucef S, Delannoy AS, et al. High plasma level of soluble tumor necrosis factor receptor type II (sTNFRII) in asymptomatic HIV-1-infected patients. Infection 1996; 24: 213-217.
162. Godfried MH, van der Poll T, Mulder JW, et al. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. J Acquired Imm Def Synd & Human Retrovirol 1995; 10: 531-539.
163. Howard OM, Clouse KA, Smith C, et al. Soluble tumor necrosis factor receptor: inhibition of human immunodeficiency virus activation. Proc Natl Acad Sci USA 1993; 90: 2335-2339.
164. Ashkenazi A, Marsters SA, Capon DJ, et al. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 1991; 88: 10535-10539.
165. Lesslauer W, Tabuchi H, Gentz R, et al. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 1991; 21: 2883-2886.
166. Fisher CJ, Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The soluble TNF receptor sepsis study group. N Engl J Med 1996; 334: 1697-1702.
167. Leighton A, Abraham E, Glauser M, et al. TNF-R55-IgG1 (Ro-45-2081) in severe sepsis shock: Rationale for design of the phase III protocol. Eur Cytokine Netw 1996; 7: 282.
168. Piguet PF, Grau GE, Vesin C, et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992; 77: 510-514.
169. Wooley PH, Dutcher J, Widmer MB, et al. Influence of recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151: 6602-6607.
170. Klinkert WEF, Kojima K, Lesslauer W, et al. TNF-α receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview. J Neuroimmunol 1997; 72: 163-168.
171. Renzetti LM, Gater PR. Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways. Inflamm Res 1997; 46(Suppl 2): S143-144.
172. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-147.
173. Murray KM, Dahl SL. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Ann Pharmacother 1997; 31: 1335-1338.
174. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-259.
175. Symons JA, Eastgate JA Duff GW. Purification and characterization of a novel soluble receptor for interleukin 1. J Exp Med 1991; 174: 1251-1254.
176. Svenson M, Hansen MB, Heegaard P, et al. Specific binding of interleukin 1 (IL-1)β and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I. Cytokine 1993; 5: 427-435.
177. Dower SK, Wignall JM, Schooley K, et al. Retention of ligand binding activity by the extracellular domain of the IL-1 receptor. J Immunol 1991; 142: 4314-4320.
178. Fanslow WC, Sims JE, Sassenfeld H, et al. Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science 1990; 248: 739-742.
179. Jacobs CA, Baker PE, Roux ER, et al. Experimental autoimmune encephalomyelitis is exacerbated by IL-1α and suppressed by soluble IL-1 receptor. J Immunol 1991; 148: 2983-2989.
180. Mullarkey MF, Leiferman KM, Peters MS, et al. Human cutaneous allergic latephase response is inhibited by soluble IL-1 receptor. J Immunol 1994; 152: 2033-2041.
181. Eastgate JA, Symons JA Duff GW. Identification of an interleukin-1β binding protein in human plasma. FEBS Lett. 1990; 260: 213-216.
182. Symons JA, Young PR Duff GW. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1β precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA 1995; 92: 1714-1718.
183. Burger D, Chicheportiche R, Giri JG, et al. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 1995; 96: 38-41.
184. Rosenbaum JT, Boney RS. Use of a soluble interleukin-1 receptor to inhibit ocular inflammation. Curr Eye Res 1991; 10: 1137-1139.
185. Ulich TR, Yi ES, Yin S, et al. Intratracheal administration of endotoxin and cytokines. VII. The soluble interleukin-1 receptor and the soluble tumor necrosis factor receptor II (p80) inhibit acute inflammation. Clin Immunol Immunopathol 1994; 72: 137-140.
186. Peters M, Schirmacher P, Goldschmitt J, et al. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med 1997; 185: 755-766.
187. Mullberg, J, Durie FH, Otten-Evans C, et al. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 1995; 5198-5205.
188. Gallea-Robache S, Morand V, Millet S, et al. A metalloprotease inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine 1997; 9: 340-346.
189. Mullberg J, Schooltink H, Stoyan T, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 1993; 23: 473-480.
190. Lust JA, Jelinek DF, Donovan KA, et al. Sequence, expression and function of an mRNA encoding a soluble form of the human interleukin-6 receptor (sIL-6R). Curr Top Microbiol Immunol 1995; 194: 199-206.
191. Korholz D, Nussbaum P, Pafferath B, et al. Activation of protein kinase C induces de novo synthesis of the soluble interleukin-6 receptor in human B cells. Scand J Immunol 1994; 40: 515-520.
192. Novick D, Engelmann H, Wallach D, et al. Soluble cytokine receptors are present in normal human urine. J Exp Med 1989; 170: 1409-1414.
193. Frieling JT, Sauerwein RW, Wijdenes J, et al. Soluble interleukin-6 receptor in biological fluids from human origin. Cytokine 1994; 6: 376-381.
194. Mihara M, Moriya Y, Kishimoto T, et al. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol 1995; 34: 321-325.
195. Mitsuyama K, Toyonaga A, Sasaki E, et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 1995; 36: 45-49.
196. Yokoyama A, Kohno N, Hirasawa Y, et al. Evaluation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases. Clin Exp Immunol 1995; 100: 325-329.
197. Jakobsen PH, McKay V, Morris-Jones SD, et al. Increased concentrations of interleukin-6 and interleukin-1 receptor antagonist and decreased concentrations of beta-2-glycoprotein I in Gambian children with cerebral malaria. Infect Immun 1994; 62: 4374-4379.
198. Gaillard JP, Bataille R, Brailly H, et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 1993; 23: 820-824.
199. Gaillard JP, Liautard J, Klein B, et al. Major role of the soluble interleukin-6/ interleukin-6 receptor complex in the proliferation of interleukin-6-dependent human myeloma cell lines. Eur J Immunol 1997; 27: 3332-3340.
200. Greipp PR. Prognosis in myeloma. Mayo Clin Proc 1994; 69: 895-902.
201. Frieling JT, van Deuren M, Wijdenes J, et al. Circulating interleukin-6 receptor in patients with sepsis syndrome. J Infect Dis 1995; 171: 469-472.
202. Maes M, Meltzer HY Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994; 89: 346-351.
203. De Benedetti F, Massa M, Pignatti P, et al. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994; 93: 2114-2119.
204. Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993; 82: 1120-1126.
205. Osawa H, Josimovic-Alasevic O Diamantstein T. Interleukin-2 receptors are released by cells in vitro and in vivo. I. Detection of soluble interleukin-2 receptors in cell culture supernatants and in the serum of mice by immunoradiometric assay. Eur J Immunol 1986; 16: 467-469.
206. Wagner DK, York-Jolley J, Malek TR, et al. Antigen-specific murine T cell clones produce soluble interleukin-2 receptor on stimulation with specific antigen. J Immunol 1986; 137: 592-596.
207. Symons JA, Wood NC, Di Giovine F, et al. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol 1988; 141: 2612-2618.
208. Barral-Netto M, Barral A, Santos SB, et al. Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis. J Immunol 1991; 147: 281-284.
209. Richards JM, Mick R, Latta JM, et al. Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood 1990; 76: 1941-1945.
210. Ambrosetti A, Nadali G, Vinante F, et al. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome. Cancer 1993; 72: 201-206.
211. Kamihira S, Atogami S, Sohda H, et al. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 1994; 73: 2753-2758.
212. Prince HE, Kleinman S Williams AE. Soluble IL-2 receptor levels in serum from blood donors seropositive for HIV. J Immunol 1988; 140: 1139-1141.
213. Honda M, Kitamura K, Matsuda K, et al. Soluble IL-2 receptor in AIDS. Correlation of its serum level with the classification of HIV-induced diseases and its characterization. J Immunol 1989; 142: 4248-4255.
214. Semenzato G, Bambara LM, Biasi D, et al. Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. J Clin Immunol 1988; 8: 447-452.
215. Tokano Y, Murashima A, Takasaki Y, et al. Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus. Ann Rheum Dis 1989; 48: 803-809.
216. Josimovic-Alasevic O, Feldmeier H, Zwingenberger K, et al. Interleukin 2 receptor in patients with localized and systemic parasitic diseases. Clin Exp Immunol 1988; 72: 249-254.
217. Brown AE, Rieder T Webster HK. Prolonged elevations of soluble interleukin-2 receptors in tuberculosis. Am Rev Respir Dis 1989; 139: 1036-1038.
218. Muller C, Knoflach P Zielinski CC. Soluble interleukin 2 receptor in acute viral hepatitis and chronic liver disease. Hepatology 1989; 10: 928-932.
219. Perkins JD, Nelson DL, Rakela J, et al. Soluble interleukin 2 receptor level in liver allograft recipients: an indicator of rejection. Transplantation 1989; 47: 77-81.
220. Bock GH, Neu L, Long C, et al. An assessment of serum and urine soluble interleukin-2 receptor concentrations during renal transplant rejection. Am J Kidney Dis 1994; 23: 421-426.
221. Honda M, Kitamura K, Takeshita T, et al. Identification of a soluble IL-2 receptor β-chain from human lymphoid cell line cells. J Immunol 1990; 145: 4131-4135.
222. Harada N, Castle BE, Gorman DM, et al. Expression cloning of a cDNA encoding the murine interleukin 4 receptor based on ligand binding. Proc Natl Acad Sci USA 1990; 87: 857-861.
223. Idzerda RL, March CJ, Mosley B, et al. Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily. J Exp Med 1990; 171: 861-873.
224. Blum H, Wolf M, Enssle K, et al. Two distinct stimulus-dependent pathways lead to production of soluble murine interleukin-4 receptor. J Immunol 1996; 157: 1846-1853.
225. Konig B, Neuber K Konig W. Responsiveness of peripheral blood mononuclear cells from normal and atopic donors to microbial superantigens. Int Arch Allergy Immunol 1995; 106: 124-133.
226. Maliszewski CR, Sato TA, VandenBos T, et al. Cytokine receptors and B cell functions. I. Recombinant soluble receptors specifically inhibit IL-4 and IL-4 induced B cell activities in vitro. J Immunol 1990; 144: 3028-3033.
227. Fanslow WC, Clifford KN, Park LS, et al. Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. J Immunol 1991; 147: 535-540.
228. Gessner A, Schroppel K, Will A, et al. Recombinant soluble interleukin-4 (IL-4) receptor acts as an antagonist of IL-4 in murine cutaneous leishmaniasis. Infect Immunol 1994; 62: 4112-4117.
229. Puccetti P, Mencacci A, Cenci E, et al. Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J Infect Dis 1994; 169: 1325-1331.
230. Garrone P, Djossou O, Galizzi JP, et al. A recombinant extracellular domain of the human interleukin 4 receptor inhibits the biological effects of interleukin 4 on T and B lymphocytes. Eur J Immunol 1991; 21: 1365-1369.
231. Mita SA, Tominaga A, Hitoshi Y, et al. Characterization of high-affinity receptors for interleukin 5 on interleukin 5-dependent cell lines. Proc Natl Acad Sci USA 1989; 86: 2311-2315.
232. Takaki S, Tominaga A, Hitoshi Y, et al. Molecular cloning and expression of the murine interleukin-5 receptor. EMBO J 1990; 9: 4367-4374.
233. Yasruel Z, Humbert M, Kotsimbos TC, et al. Membrane bound and soluble α IL-5 receptor mRNA in the bronchial mucosa of atopic and nonatopic asthmatics. Am J Resp Crit Care Med 1997; 155: 1413-1418.
234. Pestka S, Langer JA, Zoon KC, et al. Interferons and their actions. Annu Rev Biochem 1987; 56: 727-777.
235. Branca AA, Baglioni C. Evidence that type I and II interferons have different receptors. Nature 1981; 294: 768-770.
236. Orchansky P, Novick D Rubinstein M. Type I and type II interferon receptors. J Interferon Res 1984; 4: 275-282.
237. Novick D, Cohen B Rubinstein M. Soluble interferon-α receptor molecules are present in body fluids. FEBS Lett 1992; 314: 445-448.
238. Ozmen L, Fountoulakis M, Gentz R, et al. Immunomodulation with soluble IFNγ receptor: preliminary study. Int Rev Exp Pathol 1993; 34 Pt B: 137-147.
239. Ozmen L, Roman D, Fountoulakis M, et al. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-γ receptor inhibits the onset of glomerulonephritis. Eur J Immunol 1995; 25: 6-12.
240. Noguchi M, Nakamura Y, Russell SM, et al. Interleukin-2 receptor γ chain: a functional component of the interleukin-7 receptor. Science 1993; 262: 1877-1880.
241. Clark SC, Karmen R. The human hematopoietic colony-stimulating factors. Science 1987; 236: 1229-1237.
242. Kitamura T, Sato N, Arai K, et al. Expression cloning of the human IL-3 receptor cDNA reveals a shared β subunit for the human IL-3 and GM-CSF receptors. Cell 1991; 66: 1165-1174.
243. Raines MA, Liu L, Quan SG, et al. Identification and molecular cloning of a soluble human granulocyte-macrophage colony-stimulating factor receptor. Proc Natl Acad Sci USA 1991; 88: 8203-8207.